Literature DB >> 17631740

Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.

A Ruyssen-Witrand1, L Gossec, C Salliot, M Luc, M Duclos, S Guignard, M Dougados.   

Abstract

OBJECTIVE: Tumor necrosis factor (TNF) blockers have been reported to increase the risk of infections, thrombosis, and delayed healing. However, there is little data on the risk of complications after surgery in rheumatic patients receiving TNF blockers. The aim of this study was to assess the complication rate after surgery in such patients, to assess the effect of interrupting TNF blocker therapy, and to identify other potential predictors of complications.
METHODS: This was a systematic, retrospective monocenter study of all patients treated with TNF blockers and who underwent surgery. Complications were recorded and complication rates were compared based on the type of surgery and the timing of the discontinuation of TNF blockers before surgery (above 2 or 5 half-lives). The complication rates were compared with those reported in the literature (orthopaedic procedures in RA patients: 7%, abdominal surgery: 13%).
RESULTS: Between 1997 and 2004, 770 patients were treated with TNF blockers of whom 92 underwent surgery (127 surgical procedures). The most frequent underlying disease was rheumatoid arthritis (77%). Most of the surgical procedures were orthopaedic (85%). The complication rates for orthopaedic procedures and for abdominal procedures were 13% and 43%, respectively. The infection rate after orthopaedic procedures was 6.5%. Interrupting therapy before surgery did not significantly decrease the postoperative complication risk. There were no independent factors predicting complications.
CONCLUSION: In daily practice the complication rate after surgery is high in patients treated with TNF blockers. Discontinuing TNF therapy before surgery should be considered, although this study did not clearly demonstrate its role.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631740

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  26 in total

Review 1.  Perioperative care for patients with rheumatic diseases.

Authors:  Bharath M Akkara Veetil; Tim Bongartz
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

2.  Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.

Authors:  Michael M Ward; Abhijit Dasgupta
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

3.  [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases].

Authors:  K Krüger; K Albrecht; S Rehart; R Scholz
Journal:  Z Rheumatol       Date:  2014-02       Impact factor: 1.372

Review 4.  Harnessing and modulating inflammation in strategies for bone regeneration.

Authors:  Paschalia M Mountziaris; Patrick P Spicer; F Kurtis Kasper; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2011-06-30       Impact factor: 6.389

5.  Cachexia - an intrinsic factor in wound healing.

Authors:  Michael F Y Ng
Journal:  Int Wound J       Date:  2010-04       Impact factor: 3.315

6.  Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs' administrative database study.

Authors:  Zaki Abou Zahr; Andrew Spiegelman; Maria Cantu; Bernard Ng
Journal:  Rheumatol Int       Date:  2014-09-04       Impact factor: 2.631

7.  Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis.

Authors:  Elizabeth Salt; Amanda T Wiggins; Mary Kay Rayens; Brent J Morris; David Mannino; Andrew Hoellein; Ryan P Donegan; Leslie J Crofford
Journal:  Semin Arthritis Rheum       Date:  2016-08-24       Impact factor: 5.532

8.  Depletion of bone marrow-derived macrophages perturbs the innate immune response to surgery and reduces postoperative memory dysfunction.

Authors:  Vincent Degos; Susana Vacas; Zhenying Han; Nico van Rooijen; Pierre Gressens; Hua Su; William L Young; Mervyn Maze
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

9.  Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.

Authors:  Hiroko Kunitake; Richard Hodin; Paul C Shellito; Bruce E Sands; Joshua Korzenik; Liliana Bordeianou
Journal:  J Gastrointest Surg       Date:  2008-08-16       Impact factor: 3.452

Review 10.  Perioperative management of the patient with rheumatoid arthritis.

Authors:  Megan L Krause; Eric L Matteson
Journal:  World J Orthop       Date:  2014-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.